Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Regulation of nitric oxide-sensitive guanylyl cyclase.

Friebe A, Koesling D.

Circ Res. 2003 Jul 25;93(2):96-105. Review.

2.

Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.

Mullershausen F, Russwurm M, Friebe A, Koesling D.

Circulation. 2004 Apr 13;109(14):1711-3. Epub 2004 Apr 5.

3.
4.

Desensitization of NO/cGMP signaling in smooth muscle: blood vessels versus airways.

Mullershausen F, Lange A, Mergia E, Friebe A, Koesling D.

Mol Pharmacol. 2006 Jun;69(6):1969-74. Epub 2006 Mar 1.

5.

In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.

Mullershausen F, Russwurm M, Koesling D, Friebe A.

Mol Biol Cell. 2004 Sep;15(9):4023-30. Epub 2004 Jul 7.

6.

Guanylyl cyclase: NO hits its target.

Russwurm M, Koesling D.

Biochem Soc Symp. 2004;(71):51-63. Review.

PMID:
15777012
7.

BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase.

Koglin M, Stasch JP, Behrends S.

Biochem Biophys Res Commun. 2002 Apr 12;292(4):1057-62.

PMID:
11944922
8.

Modulation of cGMP in heart failure: a new therapeutic paradigm.

Boerrigter G, Lapp H, Burnett JC.

Handb Exp Pharmacol. 2009;(191):485-506. doi: 10.1007/978-3-540-68964-5_21. Review.

10.

Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.

Wang H, Kohr MJ, Traynham CJ, Ziolo MT.

J Mol Cell Cardiol. 2009 Aug;47(2):304-14. doi: 10.1016/j.yjmcc.2009.03.021. Epub 2009 Apr 1.

11.
12.

Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.

Boerrigter G, Burnett JC Jr.

Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. Review.

PMID:
17445086
13.

[YC-1-like potentiation of nitric oxide-dependent activation of soluble guanylyl cyclase by adrenochrome].

Severina IS, Piatakova NV, Shchegolev AIu, Sidorova TA.

Biomed Khim. 2008 Nov-Dec;54(6):679-86. Russian.

PMID:
19205427
14.

Vasomotor control in mice overexpressing human endothelial nitric oxide synthase.

van Deel ED, Merkus D, van Haperen R, de Waard MC, de Crom R, Duncker DJ.

Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1144-53. Epub 2007 May 11.

16.

The alpha2beta1 isoform of guanylyl cyclase mediates plasma membrane localized nitric oxide signalling.

Bellingham M, Evans TJ.

Cell Signal. 2007 Oct;19(10):2183-93. Epub 2007 Jun 29.

PMID:
17643962
17.

Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling.

Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D.

J Cell Biol. 2003 Mar 3;160(5):719-27. Epub 2003 Feb 25.

18.

Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway.

Miraglia E, De Angelis F, Gazzano E, Hassanpour H, Bertagna A, Aldieri E, Revelli A, Ghigo D.

Reproduction. 2011 Jan;141(1):47-54. doi: 10.1530/REP-10-0151. Epub 2010 Oct 21.

19.
20.

Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.

Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A.

Eur J Pharmacol. 2007 Oct 15;572(1):12-22. Epub 2007 Jun 29.

PMID:
17659276

Supplemental Content

Support Center